Fiche du document
16 avril 2020
- doi: 10.1186/s12967-020-02340-w
- issn: 1479-5876
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12967-020-02340-w
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32299446
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1479-5876
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B856D78550C38
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
TherapyCiter ce document
P.A. Ascierto et al., « The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. », Serveur académique Lausannois, ID : 10.1186/s12967-020-02340-w
Métriques
Partage / Export
Résumé
The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treatment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected their respective personal approach.